KOREA PHARMA Co., Ltd. (KOSDAQ:032300)
South Korea · Delayed Price · Currency is KRW 8,030.00
-30.00 (-0.37%)
At close: Oct 23, 2026
KOREA PHARMA Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 87,581 | 141,787 | 166,982 | 257,943 | 233,403 | 529,520 | |
Market Cap Growth | -40.47% | -15.09% | -35.26% | 10.51% | -55.92% | 118.69% |
Enterprise Value | 93,132 | 146,597 | 151,067 | 248,815 | 222,946 | 528,191 |
Last Close Price | 8030.00 | 13000.00 | 15251.21 | 23482.14 | 21200.57 | 47987.24 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 44.04 | 3079.40 | - | 83.15 |
Forward PE | - | 82.10 | 82.10 | 82.10 | 82.10 | 112.13 |
PS Ratio | 0.93 | 1.62 | 2.05 | 3.10 | 2.88 | 6.65 |
PB Ratio | 1.19 | 2.06 | 2.34 | 3.76 | 3.90 | 9.21 |
P/TBV Ratio | 1.24 | 2.17 | 2.48 | 3.96 | 4.10 | 9.72 |
P/FCF Ratio | 11.36 | - | 34.81 | 78.44 | 40.14 | 114.12 |
P/OCF Ratio | 10.46 | 52.78 | 20.75 | 53.52 | 28.19 | 73.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.99 | 1.67 | 1.86 | 2.99 | 2.75 | 6.64 |
EV/EBITDA Ratio | 21.76 | 64.31 | 17.01 | 28.75 | 26.02 | 71.46 |
EV/EBIT Ratio | 77.64 | - | 24.82 | 42.60 | 36.03 | 105.34 |
EV/FCF Ratio | 12.08 | - | 31.49 | 75.67 | 38.34 | 113.83 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.46 | 0.57 | 0.32 | 0.51 | 0.91 | 0.94 |
Debt / EBITDA Ratio | 7.17 | 17.08 | 2.58 | 4.03 | 6.38 | 7.27 |
Debt / FCF Ratio | 4.41 | - | 4.77 | 10.60 | 9.40 | 11.58 |
Net Debt / Equity Ratio | 0.08 | 0.17 | -0.21 | -0.20 | -0.14 | -0.15 |
Net Debt / EBITDA Ratio | 1.17 | 5.00 | -1.66 | -1.55 | -0.99 | -1.19 |
Net Debt / FCF Ratio | 0.72 | -0.67 | -3.08 | -4.09 | -1.45 | -1.90 |
Asset Turnover | 0.73 | 0.73 | 0.70 | 0.66 | 0.62 | 0.76 |
Inventory Turnover | 2.74 | 2.74 | 2.46 | 2.59 | 2.67 | 2.40 |
Quick Ratio | 1.06 | 0.74 | 2.76 | 1.89 | 1.14 | 3.13 |
Current Ratio | 1.58 | 1.14 | 3.81 | 2.56 | 1.41 | 3.81 |
Return on Equity (ROE) | -1.07% | -3.77% | 5.42% | 0.13% | -1.91% | 12.25% |
Return on Assets (ROA) | 0.81% | -0.46% | 3.26% | 2.89% | 2.97% | 2.97% |
Return on Invested Capital (ROIC) | 2.11% | -1.30% | 10.57% | 0.46% | 12.37% | 11.11% |
Return on Capital Employed (ROCE) | 1.90% | -1.30% | 6.50% | 6.60% | 10.10% | 4.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.87% | -1.86% | 2.27% | 0.03% | -0.48% | 1.20% |
FCF Yield | 8.80% | -11.96% | 2.87% | 1.27% | 2.49% | 0.88% |
Payout Ratio | - | - | 14.38% | 651.04% | - | 8.56% |
Buyback Yield / Dilution | -2.06% | -9.75% | -4.06% | 3.63% | 1.22% | -12.80% |